Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GBA1 | P04062 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162411 | 0.98 | HTT (0.96) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL30530619 | 0.94 | HTT (0.89) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL1520613 | 0.94 | HTT (0.89) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL10722320 | 0.94 | HTT (0.89) | HTTMAPTNPSR1ALDH1A1CYP2C9 | |
| SCHEMBL10330512 | 0.93 | HTT (0.86) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL2538595 | 0.93 | HTT (0.86) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL14818758 | 0.92 | HTT (0.84) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL13162034 | 0.90 | HTT (0.81) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL3088384 | 0.87 | HTT (0.77) | HTTMAPTNPSR1ALDH1A1GBA1 | |
| SCHEMBL4548030 | 0.87 | HTT (0.77) | HTTMAPTNPSR1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | MAVS, SNRPE, LONP1 | HTT 4221/4885MAPT 4642/4885NPSR1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.